Pregabalin Pfizer

Country: European Union

Language: Icelandic

Source: EMA (European Medicines Agency)

Active ingredient:

pregabalín

Available from:

Upjohn EESV

ATC code:

N03AX16

INN (International Name):

pregabalin

Therapeutic group:

Antiepileptics,

Therapeutic area:

Anxiety Disorders; Epilepsy

Therapeutic indications:

Taugakvillaverkur painPregabalin Pfizer er ætlað fyrir meðferð af útlimum og central taugaverkir í fullorðnir. EpilepsyPregabalin Pfizer er fram eins og venjulega meðferð í fullorðnir með hluta flog með eða án efri almenn ákvörðun er tekin. Almenn Kvíða DisorderPregabalin Pfizer er ætlað fyrir meðferð Almenn Kvíða (HIMNUM) hjá fullorðnum.

Product summary:

Revision: 29

Authorization status:

Leyfilegt

Authorization date:

2014-04-10

Patient Information leaflet

                                56
B. FYLGISEÐILL
57
FYLGISEÐILL: UPPLÝSINGAR FYRIR NOTANDA LYFSINS
PREGABALIN PFIZER 25 MG HÖRÐ HYLKI
PREGABALIN PFIZER 50 MG HÖRÐ HYLKI
PREGABALIN PFIZER 75 MG HÖRÐ HYLKI
PREGABALIN PFIZER 100 MG HÖRÐ HYLKI
PREGABALIN PFIZER 150 MG HÖRÐ HYLKI
PREGABALIN PFIZER 200 MG HÖRÐ HYLKI
PREGABALIN PFIZER 225 MG HÖRÐ HYLKI
PREGABALIN PFIZER 300 MG HÖRÐ HYLKI
pregabalín
LESIÐ ALLAN FYLGISEÐILINN VANDLEGA ÁÐUR EN BYRJAÐ ER AÐ TAKA
LYFIÐ. Í HONUM ERU MIKILVÆGAR
UPPLÝSINGAR.
-
Geymið fylgiseðilinn. Nauðsynlegt getur verið að lesa hann
síðar.
-
Leitið til læknisins eða lyfjafræðings ef þörf er á frekari
upplýsingum.
-
Þessu lyfi hefur verið ávísað til persónulegra nota. Ekki má
gefa það öðrum. Það getur valdið
þeim skaða, jafnvel þó um sömu sjúkdómseinkenni sé að ræða.
-
Látið lækninn eða lyfjafræðing vita um allar aukaverkanir.
Þetta gildir einnig um aukaverkanir
sem ekki er minnst á í þessum fylgiseðli. Sjá kafla 4.
Í FYLGISEÐLINUM ERU EFTIRFARANDI KAFLAR:
1.
Upplýsingar um Pregabalin Pfizer og við hverju það er notað
2.
Áður en byrjað er að nota Pregabalin Pfizer
3.
Hvernig nota á Pregabalin Pfizer
4.
Hugsanlegar aukaverkanir
5.
Hvernig geyma á Pregabalin Pfizer
6.
Pakkningar og aðrar upplýsingar
1.
UPPLÝSINGAR UM PREGABALIN PFIZER OG VIÐ HVERJU ÞAÐ ER NOTAÐ
Pregabalin Pfizer tilheyrir flokki lyfja sem eru notuð við meðferð
við flogaveiki, taugaverkjum og
almennri kvíðaröskun hjá fullorðnum.
ÚTLÆGIR OG MIÐLÆGIR TAUGAVERKIR:
Pregabalin Pfizer er notað til meðhöndlunar á langvarandi
verkjum af völdum taugaskemmda. Fjöldi mismunandi sjúkdóma getur
valdið útlægum taugaverkjum,
svo sem sykursýki eða ristill. Verkjatilfinningunni hefur verið
lýst sem: hita, sviða, slætti, skoti, sting,
nístandi, krampa, verk, dofa, tilfinningaleysi, náladofa.
Skapbreytingar, svefntruflanir og þróttleysi
(þreyta) geta einnig fylgt útlægum og miðlægum taugaverkjum og
þeir geta haft áhrif á líkamlega og

                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
VIÐAUKI I
SAMANTEKT Á EIGINLEIKUM LYFS
2
1.
HEITI LYFS
Pregabalin Pfizer 25 mg hörð hylki.
Pregabalin Pfizer 50 mg hörð hylki
Pregabalin Pfizer 75 mg hörð hylki
Pregabalin Pfizer 100 mg hörð hylki
Pregabalin Pfizer 150 mg hörð hylki
Pregabalin Pfizer 200 mg hörð hylki
Pregabalin Pfizer 225 mg hörð hylki
Pregabalin Pfizer 300 mg hörð hylki
2.
INNIHALDSLÝSING
Pregabalin Pfizer 25 mg hörð hylki
Hvert hart hylki inniheldur 25 mg pregabalín.
Pregabalin Pfizer 50 mg hörð hylki
Hvert hart hylki inniheldur 50 mg pregabalin.
Pregabalin Pfizer 75 mg hörð hylki
Hvert hart hylki inniheldur 75 mg pregabalin.
_ _
Pregabalin Pfizer 100 mg hörð hylki
Hvert hart hylki inniheldur 100 mg pregabalin.
Pregabalin Pfizer 150 mg hörð hylki
Hvert hart hylki inniheldur 150 mg pregabalin.
_ _
Pregabalin Pfizer 200 mg hörð hylki
Hvert hart hylki inniheldur 200 mg pregabalin.
_ _
Pregabalin Pfizer 225 mg hörð hylki
Hvert hart hylki inniheldur 225 mg pregabalin.
Pregabalin Pfizer 300 mg hörð hylki
Hvert hart hylki inniheldur 300 mg pregabalin.
Hjálparefni með þekkta verkun
Pregabalin Pfizer 25 mg hörð hylki
Hvert hart hylki inniheldur einnig 35 mg laktósaeinhýdrat.
Pregabalin Pfizer 50 mg hörð hylki
Hvert hart hylki inniheldur einnig 70 mg laktósaeinhýdrat.
Pregabalin Pfizer 75 mg hörð hylki
Hvert hart hylki inniheldur einnig 8,25 mg laktósaeinhýdrat.
Pregabalin Pfizer 100 mg hörð hylki
Hvert hart hylki inniheldur einnig 11 mg laktósaeinhýdrat.
Pregabalin Pfizer 150 mg hörð hylki
Hvert hart hylki inniheldur einnig 16,50 mg laktósaeinhýdrat.
Pregabalin Pfizer 200 mg hard capsules
Hvert hart hylki inniheldur einnig 22 mg laktósaeinhýdrat.
3
Pregabalin Pfizer 225 mg hörð hylki
Hvert hart hylki inniheldur einnig 24,75 mg laktósaeinhýdrat.
Pregabalin Pfizer 300 mg hörð hylki
Hvert hart hylki inniheldur einnig 33 mg laktósaeinhýdrat.
Sjá lista yfir öll hjálparefni í kafla 6.1.
3.
LYFJAFORM
Hylki, hart.
Pregabalin Pfizer 25 mg hörð hylki
Hvítt, merkt „Pfizer“ á efri p
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 12-01-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 12-01-2024
Public Assessment Report Public Assessment Report Bulgarian 07-05-2014
Patient Information leaflet Patient Information leaflet Spanish 12-01-2024
Public Assessment Report Public Assessment Report Spanish 07-05-2014
Patient Information leaflet Patient Information leaflet Czech 12-01-2024
Public Assessment Report Public Assessment Report Czech 07-05-2014
Patient Information leaflet Patient Information leaflet Danish 12-01-2024
Public Assessment Report Public Assessment Report Danish 07-05-2014
Patient Information leaflet Patient Information leaflet German 12-01-2024
Public Assessment Report Public Assessment Report German 07-05-2014
Patient Information leaflet Patient Information leaflet Estonian 12-01-2024
Public Assessment Report Public Assessment Report Estonian 07-05-2014
Patient Information leaflet Patient Information leaflet Greek 12-01-2024
Public Assessment Report Public Assessment Report Greek 07-05-2014
Patient Information leaflet Patient Information leaflet English 12-01-2024
Public Assessment Report Public Assessment Report English 07-05-2014
Patient Information leaflet Patient Information leaflet French 12-01-2024
Public Assessment Report Public Assessment Report French 07-05-2014
Patient Information leaflet Patient Information leaflet Italian 12-01-2024
Public Assessment Report Public Assessment Report Italian 07-05-2014
Patient Information leaflet Patient Information leaflet Latvian 12-01-2024
Public Assessment Report Public Assessment Report Latvian 07-05-2014
Patient Information leaflet Patient Information leaflet Lithuanian 12-01-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 12-01-2024
Public Assessment Report Public Assessment Report Lithuanian 07-05-2014
Patient Information leaflet Patient Information leaflet Hungarian 12-01-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 12-01-2024
Public Assessment Report Public Assessment Report Hungarian 07-05-2014
Patient Information leaflet Patient Information leaflet Maltese 12-01-2024
Public Assessment Report Public Assessment Report Maltese 07-05-2014
Patient Information leaflet Patient Information leaflet Dutch 12-01-2024
Public Assessment Report Public Assessment Report Dutch 07-05-2014
Patient Information leaflet Patient Information leaflet Polish 12-01-2024
Public Assessment Report Public Assessment Report Polish 07-05-2014
Patient Information leaflet Patient Information leaflet Portuguese 12-01-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 12-01-2024
Public Assessment Report Public Assessment Report Portuguese 07-05-2014
Patient Information leaflet Patient Information leaflet Romanian 12-01-2024
Public Assessment Report Public Assessment Report Romanian 07-05-2014
Patient Information leaflet Patient Information leaflet Slovak 12-01-2024
Public Assessment Report Public Assessment Report Slovak 07-05-2014
Patient Information leaflet Patient Information leaflet Slovenian 12-01-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 12-01-2024
Public Assessment Report Public Assessment Report Slovenian 07-05-2014
Patient Information leaflet Patient Information leaflet Finnish 12-01-2024
Public Assessment Report Public Assessment Report Finnish 07-05-2014
Patient Information leaflet Patient Information leaflet Swedish 12-01-2024
Public Assessment Report Public Assessment Report Swedish 07-05-2014
Patient Information leaflet Patient Information leaflet Norwegian 12-01-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 12-01-2024
Patient Information leaflet Patient Information leaflet Croatian 12-01-2024
Public Assessment Report Public Assessment Report Croatian 07-05-2014

Search alerts related to this product